GlassScriptPhysician profile
Islam Eltarawy
NPI 1588815674
$3,463.00
in general payments reported to CMS, 2019-2025
32 companies · $897 in 2025
The $897 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.97 · 2020: $236 · 2021: $278 · 2022: $263 · 2023: $622 · 2024: $1,072 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.58 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $524.28 | 2020-2025 | |
| Pfizer INC. | $396.73 | 2019-2025 | |
| Novo Nordisk INC | $352.31 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $318.82 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $276.57 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $245.03 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Dexcom, INC. | $219.93 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $125.18 | 2021-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $114.82 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $99.09 | 2022-2025 | Freestyle Libre 3 |
| Noven Therapeutics, LLC | $90.26 | 2023-2024 | Xelstrym |
| Astellas Pharma US INC | $80.99 | 2024-2025 | Veozah |
| Currax Pharmaceuticals LLC | $68.77 | 2019-2023 | Nexletol |
| Eisai INC. | $62.39 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $58.27 | 2024-2025 | Spravato |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $40.15 | 2022 | |
| Inspire Medical Systems, INC. | $39.10 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $36.48 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $33.66 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.08 | 2022-2023 | |
| Gilead Sciences, INC. | $29.63 | 2020 | |
| Corium, LLC | $29.48 | 2023 | Azstarys |
| Allergan, INC. | $23.17 | 2020 | |
| Xeris Pharmaceuticals, INC. | $22.54 | 2025 | Keveyis |
| Optinose US, INC. | $22.01 | 2021 | |
| Genentech USA, INC. | $21.39 | 2021 | |
| Medtronic, INC. | $20.05 | 2024 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $18.64 | 2022 | |
| Dynavax Technologies Corporation | $18.23 | 2024 | Heplisav-B |
| Esperion Therapeutics, INC. | $15.90 | 2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $13.81 | 2020 | |
| Amarin Pharma, INC. | $13.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Islam Eltarawy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.